Dr. Scott Gottlieb: Tariffs are a very inefficient tool to reshore drug manufacturing

The Supreme Court's decision to strike down President Trump's reciprocal tariffs doesn't end his plans for pharmaceutical industry tariffs. Join us now. A former FDA commissioner uh Dr.. Scott Gotautle. He's a CNBC contributor. Serves on the boards of Aluminina, Fizer, and United Health. You you're not so sure, are you? Doesn't the pharmaceutical industry agreed to a lot of what uh the president wanted? and and are are future tariffs necessary at this point for for where President Trump wanted to go with wi ...